ETNB (89bio, Inc.) Short-Term Debt to Capital
89bio, Inc. (ETNB) delegates production and testing to third-party partners to focus on developing innovative drugs. The experienced management team enjoys high market confidence as it prepares key developments for the final stages of verification. The business relies on creating treatments for liver pathologies, which ensures consistent demand and revenue. This market valuation chart shows that this metric stands at 0.00.
Analytical breakdowns for 89bio, Inc.
This ratio measures the proportion of short-term liabilities within the equity structure, allowing investors to assess liquidity risk and the company's dependence on immediate refinancing. By analyzing changes in short-term debt relative to equity, one can diagnose the financial stability of 89bio, Inc., whose metabolic therapy development strategy relies on costly scientific partnerships and licensing deals.